Evidence map›Paper›PMID 36630749›Full record

ArticleCortex; a journal devoted to the study of the nervous system and behavior2023

The recency ratio assessed by story recall is associated with cerebrospinal fluid levels of neurodegeneration biomarkers.

Davide Bruno, Ainara Jauregi Zinkunegi, Gwendlyn Kollmorgen, Ivonne Suridjan, Norbert Wild, Cynthia Carlsson, Barbara Bendlin, Ozioma Okonkwo, Nathaniel Chin, Bruce P Hermann and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cortex; a journal devoted to the study of the nervous system and behavior, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Abnormal Forgetting Rate from the Recency Portion of a Word-List in Patients with Subjective Cognitive Decline.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026
    Article
  3. Article
  4. Predicting CDR status over 36 months with a recall-based digital cognitive biomarker.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Davide BrunoSchool of Psychology, Liverpool John Moores University, UK. Electronic address: d.bruno@ljmu.ac.uk.
Ainara Jauregi ZinkunegiSchool of Psychology, Liverpool John Moores University, UK.
Gwendlyn KollmorgenRoche Diagnostics GmbH, Penzberg, Germany.
Ivonne SuridjanRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Norbert WildRoche Diagnostics GmbH, Penzberg, Germany.
Cynthia CarlssonWisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Geriatric Research Education and Clinical Center, William S. Middleton Veterans Hospital, Madison, WI, USA.
Barbara BendlinWisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Ozioma OkonkwoWisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Nathaniel ChinWisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA.
Bruce P HermannWisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Department of Neurology, University of Wisconsin - Madison, Madison, WI, USA.
Sanjay AsthanaWisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Rebecca LanghoughWisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Sterling C JohnsonWisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Geriatric Research Education and Clinical Center, William S. Middleton Veterans Hospital, Madison, WI, USA.
Kimberly D MuellerWisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA; Department of Communication Sciences and Disorders, University of Wisconsin - Madison, Madison, WI, USA.

Funding

White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3M
The effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normalR01AG068398 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIANG, GLORIA CHIA-YI · 2020 to 2024
$2.8M
Novel Story Recall Measures as Indicators of Cognitive Decline Associated with Alzheimer's Disease and Related Disorders Biomarkers: A Collaborative Study of Existing DataR01AG070940 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Kimberly D Mueller · 2021 to 2026
$2.8M
NIA NIH HHS R01 AG037639NIA NIH HHS R01 AG068398NIA NIH HHS R01 AG070940
6 · The paper itself

Abstract

Recency refers to the information learned at the end of a study list or task. Recency forgetting, as tracked by the ratio between recency recall in immediate and delayed conditions, i.e., the recency ratio (Rr), has been applied to list-learning tasks, demonstrating its efficacy in predicting cognitive decline, conversion to mild cognitive impairment (MCI), and cerebrospinal fluid (CSF) biomarkers of neurodegeneration. However, little is known as to whether Rr can be effectively applied to story recall tasks. To address this question, data were extracted from the database of the Alzheimer's Disease Research Center at the University of Wisconsin - Madison. A total of 212 participants were included in the study. CSF biomarkers were amyloid-beta (Aβ) 40 and 42, phosphorylated (p) and total (t) tau, neurofilament light (NFL), neurogranin (Ng), and α-synuclein (a-syn). Story Recall was measured with the Logical Memory Test (LMT). We carried out Bayesian regression analyses with Rr, and other LMT scores as predictors; and CSF biomarkers (including the Aβ42/40 and p-tau/Aβ42 ratios) as outcomes. Results showed that models including Rr consistently provided best fits with the data, with few exceptions. These findings demonstrate the applicability of Rr to story recall and its sensitivity to CSF biomarkers of neurodegeneration, and encourage its inclusion when evaluating risk of neurodegeneration with story recall.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBayes TheoremBiomarkersHumansNeuronstau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsCerebrospinal fluid biomarkersDementiaMemory assessmentSerial position effectsStory recall

Identifiers

PMID36630749
PMCPMC9931664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.